查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423590

到 2030 年基层医疗POC 诊断市场预测：按产品类型、技术、样本类型、分销管道、最终用户和地区进行的全球分析

Primary Care POC Diagnostics Market Forecasts to 2030 - Global Analysis By Product (Urinalysis, Ambulatory Chemistry, Infectious Diseases Testing Kits and Other Products), Technology, Sample Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球基层医疗POC 诊断市场规模为 167 亿美元，预计在预测期内复合年增长率为 8.5%，到 2030 年将达到 295 亿美元。

基层医疗职业点 (POC) 诊断是基层医疗环境中使用的诊断工具和测试，使医疗保健专业人员能够立即获得靠近患者的测试结果。这些测试在患者的护理点或附近进行，可以快速轻鬆地存取诊断资料，以便快速做出临床决策。在患者就诊期间，这些测试可以提供快速资料（通常在几分钟内），使负责人能够快速做出临床决策。在基层医疗机构中维持高品质的测试和可靠的观察需要 POC 诊断，以确保准确性、可靠性并符合监管标准。

据世界卫生组织 (WHO) 称，全球约有 3.54 亿人乙型肝炎或丙型肝炎呈阳性，但仍未被诊断和治疗。世界卫生组织的目标是到2030年新增感染病例减少90%，死亡人数减少65%。

医疗保健环境中对 POC 解决方案的需求

对 POC 解决方案的需求推动了患者护理点快速检测的可用性。这使得在基层医疗中遇到患者时能够快速访问诊断信息，从而实现快速临床选择和及时治疗。这种诊断方法无需将样本运送到中央测试设施，从而显着加快了测试结果的速度。快速存取此类资讯可以促进基层医疗机构更有效的工作流程，并加快患者治疗速度，尤其是在紧急情况下。

较低的医疗费用和财务限制所带来的价格压力

报销和使用点 (POC) 诊断测试报销的减少可能会导致患者和医疗机构的成本增加。因此，某些测试的成本和可用性可能会降低，特别是在小型基层医疗机构和弱势社区。此外，财务限制迫使医疗机构选择更便宜、品质较低的现场护理 (POC) 诊断测试，从而损害了测试覆盖范围、准确性和可靠性，阻碍了市场成长。

即时诊断结果的需求

速效结果的主要目的是加速基层医疗机构的临床决策。护理点 (POC) 诊断使医疗保健专业人员能够在单次就诊中快速、明智地决定如何最好地治疗患者。这些诊断无需中心实验室，从而大大缩短了检测结果的时间。这种资讯的快速可用性确保了及时干预并加快了诊断过程。

缺乏准确性和可靠性

基层医疗POC 诊断测试的不准确或不可靠的结果可能导致误诊、无效治疗和延误必要的治疗。这可能会对健康结果产生不利影响并威胁患者安全。当医疗保健专业人员和机构使用有错误记录的基层医疗POC 诊断测试时，患者可能会对测试不满意或失去信心。患者对医疗照护的信任和满意度可能会受到影响。

COVID-19 的影响

快速、轻鬆地进行 SARS-CoV-2 检测的需求导致了对快速护理点诊断的需求激增。在基层医疗机构中，分子 POC 检测和侧流检测 (LFA) 等技术已成为快速识别 COVID-19 的关键。此外，远端医疗服务和远距测试选项已变得普遍，以试图减少接触并保持社会隔离。因此，一些 POC 测试已适用于远端医疗，允许患者在远端医疗提供者的监督下在家中进行测试。

预计门诊化学将成为预测期内最大的领域

门诊化学领域预计将出现良好的成长。术语「门诊化学」描述了在传统实验室环境之外进行的生化分析或化学测试，通常是在护理点 (POC) 或门诊治疗环境中进行。其主要目的是快速且准确地收集基本生物化学检验观察，以便在门诊和基层医疗遇到患者时快速做出临床决策。当在门诊进行生物化学检验时，患者可以前往不太集中的设施进行常规检测，这可能会节省时间并促进诊断。

侧向流动试验法（LFA）产业预计在预测期内复合年增长率最高

侧向流动试验法（LFA）领域预计在预测期内复合年增长率最高。这些测试旨在确定生物样本（例如血液、尿液、唾液或其他体液）中是否存在特定分析物。这些测试适用于基层医疗和护理点 (POC) 环境，在这些环境中，快速观察对于及时进行临床选择、推动市场成长至关重要。

占比最大的地区：

预计北美在预测期内将占据最大的市场占有率，因为美国大量基层医疗机构使用 POC 设备，并且该区域市场的很大一部分预计将占据初级设置的最大市场份额。它还与提供产品和服务的大公司的存在有关。医疗保险和医疗补助服务中心敦促医疗保健提供者发起病人参与倡议。这以及学术机构为医疗保健研究和开发提供的资金筹措正在推动该地区的市场成长。

复合年增长率最高的地区：

亚太地区预计在预测期内将经历最高的复合年增长率，因为该地区比其他亚太地区相对更加发达，拥有大量尖端和创造性的 POC 诊断解决方案。另一个关键驱动因素是初级家庭医疗保健和支持性护理环境对这些解决方案的需求不断增长。这是因为越来越多的公司正在开发该领域未实现的潜力。此外，由于公众越来越意识到需要早期诊断疾病以提高患者存活率，预计亚太市场将会发展。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球基层医疗POC 诊断市场：依产品

  • 尿液检查
  • 门诊化学
  • 传染病检查套件
  • 血脂测试
  • 血糖值监测装置
  • 血液学检测设备
  • 血气/电解质
  • Hb1Ac 测试
  • 自体免疫疾病
  • 凝血监测装置
  • 心臟标记
  • 甲状腺刺激素装置
  • 药物滥用测试
  • 怀孕和生育测试产品
  • 其他产品

第六章全球基层医疗POC 诊断市场：依技术分类

  • 免疫学测试
  • 侧向流动试验法（LFA）
  • 分子诊断
  • 临床化学
  • 电化学和生物感测器技术
  • 其他技术

第七章全球基层医疗POC 诊断市场：依样本类型

  • 尿
  • 血
  • 鼻和口咽拭子
  • 其他样品类型

第八章全球基层医疗POC 诊断市场：按分销管道

  • 药局
  • 零售诊所
  • 电子通讯平台
  • 其他分销管道

第九章全球基层医疗POC 诊断市场：依最终用户分类

  • 居家照护和自我测试
  • 医院
  • 重症监护中心及重症监护中心
  • 门诊护理设施
  • 临床实验室

第10章全球基层医疗POC诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • BD Biosciences
  • Roche Diagnostics
  • Abbott Laboratories
  • bioMerieux
  • Instrumentation Laboratory
  • Quidel Corporation
  • Danaher Corporation
  • Siemens Healthcare
  • Agilent Technologies
  • Decode Genetics
  • Axis-Shield
  • Becton Dickinson
  • Nova Biomedical
  • Trividia Health, Inc.
  • OraSure Technologies, Inc.
  • Abaxis
Product Code: SMRC24824

According to Stratistics MRC, the Global Primary Care POC Diagnostics Market is accounted for $16.7 billion in 2023 and is expected to reach $29.5 billion by 2030 growing at a CAGR of 8.5% during the forecast period. Primary Care Point-of-Care (POC) Diagnostics are diagnostic tools and tests used in primary care settings that enable medical professionals to get test results right away in close proximity to the patient. These tests are carried out at the point of patient care, or in close proximity to it, providing quick and easy access to diagnostic data for prompt clinical decision-making. During patient consultations, these tests enable healthcare practitioners to make prompt clinical judgments since they yield data quickly often in a matter of minutes. Maintaining high-quality testing and dependable findings in primary care settings requires POC diagnostics to ensure accuracy, dependability, and compliance with regulatory criteria.

According to the World Health Organization (WHO), approximately 354 million people globally are hepatitis B or C positive, and diagnosis and treatment are unavailable. The WHO aims to control and reduce new infections by 90% and deaths by 65% by 2030.

Market Dynamics:

Driver:

Demand for point-of-care solutions in healthcare settings

The availability of rapid testing at the point of patient care is encouraged by the need for point-of-care solutions. This allows for quick clinical choices and timely treatments during patient consultations in primary care by providing quick access to diagnostic information. This diagnostics speeds up test results considerably by removing the requirement to ship samples to centralized laboratories. This quick access to information facilitates more effective workflows in primary care settings and speeds up patient care, especially for urgent situations which further enhance the growth of the market.

Restraint:

Price pressure as a result of reduced reimbursement and financial limitations

Lower reimbursements or reimbursement for point-of-care (POC) diagnostic tests may result in higher expenses for patients or healthcare institutions. This may result in a decrease in the cost or availability of certain tests, particularly for smaller primary care clinics or underprivileged communities. Additionally, financial restrictions may force healthcare institutions to choose less expensive, lower-quality point-of-care (POC) diagnostic tests, which might compromise test range, accuracy, or reliability with stunt in the growth of the market.

Opportunity:

Demand for immediate diagnostic results

Immediate outcomes' main objective is to speed up clinical decision-making in primary care settings. Point-of-care (POC) diagnostics allow medical professionals to quickly and intelligently decide how best to treat patients at a single visit. These diagnostics drastically shorten the time it takes to get test results by doing away with the requirement for centralized laboratories. Thus, quick information availability guarantees quick interventions and speeds up the diagnostic procedure creating wide range of opportunities for the market.

Threat:

Lack of accuracy and reliability

Results from primary care point-of-care diagnostic tests that are inaccurate or untrustworthy may result in misdiagnoses, ineffective therapies, or a delay in essential actions. This might have a detrimental effect on health outcomes and jeopardize patient safety. When primary care POC diagnostic tests with a track record of errors are used by healthcare practitioners or institutions, patients may become dissatisfied or lose faith in them. Patient trust in their medical care and satisfaction may be impacted by this.

Covid-19 Impact

Demand for rapid point-of-care (POC) diagnostics surged in response to the need for quick and easily accessible SARS-CoV-2 testing. In primary care settings, procedures such molecular POC testing and lateral flow assays (LFAs) have become indispensable for rapid COVID-19 identification. Moreover, telehealth services and remote testing choices proliferated in an attempt to reduce exposure and preserve social isolation. Thus a few POC tests were modified for use in telemedicine so that patients may take tests at home under the supervision of a remote provider.

The ambulatory chemistry segment is expected to be the largest during the forecast period

The ambulatory chemistry segment is estimated to have a lucrative growth, as the term "ambulatory chemistry" describes the practice of doing biochemical analyses or chemistry tests outside of a conventional laboratory environment, usually at point-of-care (POC) or ambulatory care settings. The principal objective is to expedite and accurately collect basic biochemistry test findings to facilitate prompt clinical decision-making during patient consultations in ambulatory or primary care settings. When biochemical tests are performed in ambulatory settings, patients can visit less centralized facilities for routine testing, which can save time and facilitate diagnosis.

The lateral flow assays (LFAs) segment is expected to have the highest CAGR during the forecast period

The lateral flow assays (LFAs) segment is anticipated to witness the highest CAGR growth during the forecast period, because these tests are easy to use, quick to complete, and reasonably priced. They are intended to find out whether a certain analyze is present in biological samples like blood, urine, saliva, or other body fluids. These tests are appropriate for use in primary care or point-of-care (POC) settings where prompt findings are essential for making timely clinical choices thus encourage the growth of the market.

Region with largest share:

North America is projected to hold the largest market share during the forecast period because so many primary care facilities in the United States use POC equipment and the significant portion of this regional market has also been linked to the existence of significant firms in the nation providing goods and services for primary settings. Healthcare providers are being urged by the Centers for Medicare & Medicaid Services to start patient engagement initiatives. The market is being driven by this as well as the availability of financing for healthcare R&D by academic institutions boost the growth of the market in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the availability of several cutting-edge and creative POC diagnostic solutions, the Asia-Pacific market is comparatively more developed than the rest of the globe. Another important growth driver is the increasing demand for these solutions in primary home healthcare and supported healthcare settings. This is explained by the fact that more businesses are taking use of the unrealized potential in the area. Furthermore, it is anticipated that the Asia Pacific market would develop as a result of rising public awareness of the need of early illness diagnosis to increase patient survival rates.

Key players in the market

Some of the key players profiled in the Primary Care POC Diagnostics Market include BD Biosciences, Roche Diagnostics, Abbott Laboratories, bioMerieux, Instrumentation Laboratory, Quidel Corporation, Danaher Corporation, Siemens Healthcare, Agilent Technologies, Decode Genetics, Axis-Shield, Becton Dickinson, Nova Biomedical, Trividia Health, Inc., OraSure Technologies, Inc. and Abaxis

Key Developments:

In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

In November 2023, BD a leading global medical technology company, and Bio Farma, a state-owned life science company in Indonesia, signed a memorandum of understanding (MOU) for a joint effort to combat tuberculosis (TB)

In September 2023, bbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Products Covered:

  • Urinalysis
  • Ambulatory Chemistry
  • Infectious Diseases Testing Kits
  • Lipid Testing
  • Glucose Monitoring Devices
  • Hematology Testing Devices
  • Blood Gas/Electrolytes
  • Hb1Ac Testing
  • Autoimmune Disease
  • Coagulation Monitoring Devices
  • Cardiac Markers
  • Thyroid Stimulating Hormone Devices
  • Drug Abuse Testing
  • Pregnancy & Fertility Testing Products
  • Other Products

Technologies Covered:

  • Immunoassays
  • Lateral Flow Assays (LFAs)
  • Molecular Diagnostics
  • Clinical Chemistry
  • Electrochemical & Biosensor Technologies
  • Other Technologies

Sample Types Covered:

  • Urine
  • Blood
  • Nasal & Oropharyngeal Swabs
  • Other Sample Types

Distribution Channels Covered:

  • Pharmacies
  • Retail clinics
  • E-comm. Platforms
  • Other Distribution Channels

End Users Covered:

  • Home Care & Self Testing
  • Hospitals
  • Critical Care Centers & Urgent care centers
  • Ambulatory Care Facilities
  • Clinical Laboratories

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Primary Care POC Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Urinalysis
  • 5.3 Ambulatory Chemistry
  • 5.4 Infectious Diseases Testing Kits
  • 5.5 Lipid Testing
  • 5.6 Glucose Monitoring Devices
  • 5.7 Hematology Testing Devices
  • 5.8 Blood Gas/Electrolytes
  • 5.9 Hb1Ac Testing
  • 5.10 Autoimmune Disease
  • 5.11 Coagulation Monitoring Devices
  • 5.12 Cardiac Markers
  • 5.13 Thyroid Stimulating Hormone Devices
  • 5.14 Drug Abuse Testing
  • 5.15 Pregnancy & Fertility Testing Products
  • 5.16 Other Products

6 Global Primary Care POC Diagnostics Market, By Technology

  • 6.1 Introduction
  • 6.2 Immunoassays
  • 6.3 Lateral Flow Assays (LFAs)
  • 6.4 Molecular Diagnostics
  • 6.5 Clinical Chemistry
  • 6.6 Electrochemical & Biosensor Technologies
  • 6.7 Other Technologies

7 Global Primary Care POC Diagnostics Market, By Sample Type

  • 7.1 Introduction
  • 7.2 Urine
  • 7.3 Blood
  • 7.4 Nasal & Oropharyngeal Swabs
  • 7.5 Other Sample Types

8 Global Primary Care POC Diagnostics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Pharmacies
  • 8.3 Retail clinics
  • 8.4 E-comm. Platforms
  • 8.5 Other Distribution Channels

9 Global Primary Care POC Diagnostics Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care & Self Testing
  • 9.3 Hospitals
  • 9.4 Critical Care Centers & Urgent care centers
  • 9.5 Ambulatory Care Facilities
  • 9.6 Clinical Laboratories

10 Global Primary Care POC Diagnostics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 BD Biosciences
  • 12.2 Roche Diagnostics
  • 12.3 Abbott Laboratories
  • 12.4 bioMerieux
  • 12.5 Instrumentation Laboratory
  • 12.6 Quidel Corporation
  • 12.7 Danaher Corporation
  • 12.8 Siemens Healthcare
  • 12.9 Agilent Technologies
  • 12.10 Decode Genetics
  • 12.11 Axis-Shield
  • 12.12 Becton Dickinson
  • 12.13 Nova Biomedical
  • 12.14 Trividia Health, Inc.
  • 12.15 OraSure Technologies, Inc.
  • 12.16 Abaxis

List of Tables

  • Table 1 Global Primary Care POC Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Primary Care POC Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Primary Care POC Diagnostics Market Outlook, By Urinalysis (2021-2030) ($MN)
  • Table 4 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Chemistry (2021-2030) ($MN)
  • Table 5 Global Primary Care POC Diagnostics Market Outlook, By Infectious Diseases Testing Kits (2021-2030) ($MN)
  • Table 6 Global Primary Care POC Diagnostics Market Outlook, By Lipid Testing (2021-2030) ($MN)
  • Table 7 Global Primary Care POC Diagnostics Market Outlook, By Glucose Monitoring Devices (2021-2030) ($MN)
  • Table 8 Global Primary Care POC Diagnostics Market Outlook, By Hematology Testing Devices (2021-2030) ($MN)
  • Table 9 Global Primary Care POC Diagnostics Market Outlook, By Blood Gas/Electrolytes (2021-2030) ($MN)
  • Table 10 Global Primary Care POC Diagnostics Market Outlook, By Hb1Ac Testing (2021-2030) ($MN)
  • Table 11 Global Primary Care POC Diagnostics Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 12 Global Primary Care POC Diagnostics Market Outlook, By Coagulation Monitoring Devices (2021-2030) ($MN)
  • Table 13 Global Primary Care POC Diagnostics Market Outlook, By Cardiac Markers (2021-2030) ($MN)
  • Table 14 Global Primary Care POC Diagnostics Market Outlook, By Thyroid Stimulating Hormone Devices (2021-2030) ($MN)
  • Table 15 Global Primary Care POC Diagnostics Market Outlook, By Drug Abuse Testing (2021-2030) ($MN)
  • Table 16 Global Primary Care POC Diagnostics Market Outlook, By Pregnancy & Fertility Testing Products (2021-2030) ($MN)
  • Table 17 Global Primary Care POC Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 18 Global Primary Care POC Diagnostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 19 Global Primary Care POC Diagnostics Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 20 Global Primary Care POC Diagnostics Market Outlook, By Lateral Flow Assays (LFAs) (2021-2030) ($MN)
  • Table 21 Global Primary Care POC Diagnostics Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 22 Global Primary Care POC Diagnostics Market Outlook, By Clinical Chemistry (2021-2030) ($MN)
  • Table 23 Global Primary Care POC Diagnostics Market Outlook, By Electrochemical & Biosensor Technologies (2021-2030) ($MN)
  • Table 24 Global Primary Care POC Diagnostics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 25 Global Primary Care POC Diagnostics Market Outlook, By Sample Type (2021-2030) ($MN)
  • Table 26 Global Primary Care POC Diagnostics Market Outlook, By Urine (2021-2030) ($MN)
  • Table 27 Global Primary Care POC Diagnostics Market Outlook, By Blood (2021-2030) ($MN)
  • Table 28 Global Primary Care POC Diagnostics Market Outlook, By Nasal & Oropharyngeal Swabs (2021-2030) ($MN)
  • Table 29 Global Primary Care POC Diagnostics Market Outlook, By Other Sample Types (2021-2030) ($MN)
  • Table 30 Global Primary Care POC Diagnostics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Primary Care POC Diagnostics Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 32 Global Primary Care POC Diagnostics Market Outlook, By Retail clinics (2021-2030) ($MN)
  • Table 33 Global Primary Care POC Diagnostics Market Outlook, By E-comm. Platforms (2021-2030) ($MN)
  • Table 34 Global Primary Care POC Diagnostics Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Global Primary Care POC Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Primary Care POC Diagnostics Market Outlook, By Home Care & Self Testing (2021-2030) ($MN)
  • Table 37 Global Primary Care POC Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Primary Care POC Diagnostics Market Outlook, By Critical Care Centers & Urgent care centers (2021-2030) ($MN)
  • Table 39 Global Primary Care POC Diagnostics Market Outlook, By Ambulatory Care Facilities (2021-2030) ($MN)
  • Table 40 Global Primary Care POC Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.